Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206179 | 1.00 | SLC7A5 (0.41) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL3162091 | 0.78 | DPP4 (0.44) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL27510202 | 0.78 | DPP4 (0.44) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL23975825 | 0.77 | DPP4 (0.47) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL355353 | 0.77 | DPP4 (0.47) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL10451323 | 0.77 | DPP4 (0.47) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL356236 | 0.75 | DPP4 (0.45) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL20198229 | 0.75 | — | — | |
| Lithium SCHEMBL8741925 | 0.74 | CTSS (0.33) | — | |
| SCHEMBL788069 | 0.74 | DPP4 (0.44) | SLC7A5DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | SLC7A5 3733/4885DPP4 1075/4885DPP8 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.